Publications by authors named "Damien Kaukonen"
Prognostic factors, such as the Human Epidermal growth factor Receptor 2 (HER2) and Estrogen Receptor (ER) influence distant recurrence-free survival (RFS) in breast cancer. This study aims to evaluate the interaction between HER2 and ER status with RFS, and if that interaction influences where the metastasis is located. To do this, we used a study population of all women diagnosed with non-metastatic, invasive breast cancer in Stockholm from 2007 to 2020.
View Article and Find Full Text PDFArticle Synopsis
- The phase II trial ICORG10-05 examined the effects of chemotherapy in combination with trastuzumab, lapatinib, or both on patients with HER2+ breast cancer, focusing on changes in circulating immune cells.
- Researchers analyzed blood samples to assess immune cell cytotoxicity, phenotype, and genotype before and after neo-adjuvant treatment, along with evaluating the impact of pembrolizumab on immune activity.
- Results showed that treatment reduced the cytotoxic capability of immune cells, altered their composition, and identified potential biomarkers for treatment response through the analysis of pembrolizumab's effects on immune cell activity.
Background: The role of histone modifications is poorly characterized in breast cancer, especially within the major subtypes. While epigenetic modifications may enhance the adaptability of a cell to both therapy and the surrounding environment, the mechanisms by which this is accomplished remains unclear. In this study we focus on the HER2 subtype and investigate two histone trimethylations that occur on the histone 3; the trimethylation located at lysine 4 (H3K4me3) found in active promoters and the trimethylation located at lysine 27 (H3K27me3) that correlates with gene repression.
View Article and Find Full Text PDF